AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Pyrimidine oxygenase (EC 1.14.99.46, gene RutA) is an enzyme characterised from Escherichia coli with systematic name uracil,FMNH2:oxygen oxidoreductase (uracil hydroxylating, ring-opening). It catalyses two related oxidation reactions which act on pyrimidine nucleobases. The overall effect of the first example is to convert uracil to (Z)-3-ureidoacrylic acid with molecular oxygen as the oxidant and flavin mononucleotide (FMN) as a cofactor. The enzyme also requires nicotinamide adenine dinucleotide (NADH):
Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. It was synthesized by a French team working for Rhone-Poulenc & Rorer S.A. Pagoclone belongs to the class of nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It was never commercialised. It binds with roughly equivalent high affinity (0.7–9.1 nM) to the benzodiazepine binding site of human GABAA receptors containing either an α1, α2, α3 or α5 subunit. It is a partial agonist at α1-, α2- and α5-containing GABAA receptors and a full agonist at receptors containing an α3 subunit. In rats 5′-hydroxypagoclone was identified as a major metabolite. This metabolite has a considerably greater efficacy at the α1 subtype than the parent compound and was shown to have significant anxiolytic-like activity and to produce sedation. In contrast to zopiclone, pagoclone produces anxiolytic effects with little sedative or amnestic actions at low doses (0.3mg to 1.2mg per day). The pharmacologist David Nutt has suggested pagoclone as a possible base from which to make a better social drug, as it produces the positive effects of alcohol, such as relaxation and sociability, but without also causing the negative effects like aggression, amnesia, nausea, loss of coordination and liver damage. Its effect can be quickly reversed by the action of flumazenil, which is already used as an antidote to benzodiazepine overdose.
== Safety and tolerability == Across clinical studies, icotrokinra has demonstrated a favorable safety profile. In phase III trials for plaque psoriasis, the most common adverse events were upper respiratory tract infections and headache. Pooled safety data from multiple studies showed similar rates of adverse events between icotrokinra and comparator groups.
This part of the County of London was transferred to the new London Borough of Newham in Outer London and Newham Council was therefore an education authority. The ILEA had a somewhat anomalous legal status. Technically the GLC itself was the education authority for inner London, but it was both administratively difficult and politically questionable to allow outer London members of the GLC to have an input. Therefore, the GLC delegated responsibility to the ILEA as a 'special committee', consisting of the members of the GLC from the Inner London area, plus one member delegated from each of the inner London boroughs and the City of London. Those who were members of both the GLC and the ILEA tended to concentrate on one duty only, although they attended the meetings of both bodies.
Sources: en.wikipedia.org
Although creatinine is eliminated more slowly than iohexol, it can be determined immediately in many veterinary practices photometric even without the involvement of a specialized laboratory. In advanced kidney disease, the blood count shows a decrease in the number of red blood cells and thus the hematocrit without a change in the blood pigment load and the cell sizes of the red blood cells and without signs of new blood cell formation (normochromic, normocytic, aregenerative anemia).
Vopratelimab (JTX-4014) by Jounce Therapeutics As of 2020 entered Phase I trial Spartalizumab (PDR001) is a PD-1 inhibitor developed by Novartis to treat both solid tumors and lymphomas, which as of 2018 has entered Phase III trials. Camrelizumab (SHR1210) is an anti-PD-1 monoclonal antibody introduced by Jiangsu HengRui Medicine Co., Ltd. that recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent Biologics and Eli Lilly for patients with non-small cell lung cancer (NSCLC). INCMGA00012 (MGA012) is a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics. AMP-224 by AstraZeneca/MedImmune and GlaxoSmithKline AMP-514 (MEDI0680) by AstraZeneca Acrixolimab (YBL-006) by Y-Biologics Sasanlimab by Pfizer
If a crystal has three axes at right angles to each other then, if they are equivalent, the crystal is isotropic, if two are equivalent and the third different, the crystal is uniaxial, and if all three are different, the crystal is biaxial. In 1822 John Herschel proposed a causal relationship between the handedness of quartz crystals (right- or left-handed) and the direction of their optical rotation. In 1840 Friedrich Ludwig Hünefeld described the first crystallization of a protein; Hünefeld obtained lamellar crystals (later identified as haemoglobin) by putting the blood of an earthworm between two slides.
Sources: en.wikipedia.org
Once a sequence has been isolated, it must be inserted into a vector. The easiest way to do this is to cut the vector DNA using restriction enzymes; if the same enzymes were used to isolate the target sequence, then the same "overhang" sequences will be created on each end allowing for hybridization. Once the target gene has hybridized to the vector DNA, they can be joined using a DNA ligase. An alternative strategy uses recombination between homologous sites on the target gene and the vector sequence, eliminating the need for restriction enzymes.
β-Carbolines and harmala alkaloids like harmine and harmaline contain DMT's close analogue NMT embedded in their structures. Triptans like sumatriptan, rizatriptan, eletriptan, almotriptan, frovatriptan, and zolmitriptan, which are antimigraine agents, all contain DMT in their structures. Similarly, the pertine antipsychotics including alpertine, milipertine, oxypertine, and solypertine are DMT derivatives. Bioisosteres of DMT in which the indole ring system has been replaced with a different ring system include isoDMT (an isoindole or isotryptamine), 2ZEDMA (an indolizine), and C-DMT (an indene), among others. The homologues of DMT in which the alkyl side chain has been shortened or lengthened by one carbon atom are gramine and dimethylhomotryptamine (DMHT), respectively. Further-extended homologues are also known. Deuterated isotopologues of DMT include deudimethyltryptamine (DMT-d10) or CYB004 (HLP004), SPL028 (D2-DMT; α,α-dideutero-DMT), and DMT-d4 (α,α,β,β-tetradeutero-DMT). Prodrugs of DMT such as 1-benzoyl-DMT and N-phosphonooxymethyl-DMT (N-POM-DMT) have also been described. Many of DMT's analogues and derivatives are serotonin receptor modulators and/or serotonergic psychedelics similarly to DMT itself.
2025 Steven Henikoff, for his transformative research on genome organization and gene expression. 2024 Winrich Freiwald, Nancy Kanwisher, Margaret Livingstone, Doris Tsao for discovering how and where in the brain face recognition occurs. 2023 Wolfgang Baumeister, for his pioneering work in the development of cryo-electron tomography and his insights into the structures and functions of the protein quality control machinery 2022 Christine Holt and Erin Schuman, for their pioneering work that shed light on the role of local protein synthesis in neuronal development and function. 2021 Robert H. Singer, for his key role in revealing the dynamics of gene expression using high-resolution imaging. 2020 Katalin Karikó and Drew Weissman, for their pioneering work in the modification of nucleic acids to develop RNA therapeutics and vaccines. 2019 David Julius and Ardem Patapoutian, for their remarkable contributions to our understanding of the sensations of temperature, pain and touch. 2018 Stephen C.
Sebastião de Araújo Melo (born 24 July 1958) is a Brazilian lawyer and politician. He has been the mayor of Porto Alegre since 2021. A member of the Brazilian Democratic Movement (MDB) since 1981, he had been a member of the city council from 2001 to 2012 and was the vice-mayor of the city during the mayorship of José Fortunati. In 2018, he was elected as a state deputy to the Legislative Assembly of the state of Rio Grande do Sul, a position he held until 2021. Melo has run for mayor of Porto Alegre on three occasions. The first time, in 2016, he advanced to the second round, but was defeated by Nelson Marchezan Júnior. In 2020, he ran again and advanced once again to the second round, this time winning against Manuela d'Ávila. He would be reelected in 2024 against Maria do Rosário.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.